[1] |
LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji.
Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
|
[2] |
LIU Yi, WU Jingfang, QIN Lin, CHEN Junmiao, ZHANG Juan, CHEN Hua, NING Xiao, CAO Jin.
Related Substances in Efavirenz Tablets Based on HPLC-TRIPLE QUAD-MS/MS Technology
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 749-754.
|
[3] |
JING Tianshu, LU Guotao, WANG Shengfeng.
Risks of Pancreatic Adverse Events Associated with Tirzepatide: a Disproportionality Analysis Using Spontaneous Adverse Event Reporting System Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 669-673.
|
[4] |
CHEN Siyuan, ZHANG Yan, FENG Xue, ZHANG Caijuan, WANG Dunfang, LIU Haifan, LIU Bin, ZHU Lin, LIU Jianyao, LI Tao, YANG Weipeng.
Identification of Chemical Constituents and Determination of Multi-Component Content of Lianpo Drinking Water Decoction Based on LC-MS/MS Technology
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 554-559.
|
[5] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|
[6] |
ZHU Zhipeng, LYU Qiang, YE Xiaofei, GUO Xiaojing.
Disproportionality of Adverse Events to KRAS G12C Inhibitors Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 297-304.
|
[7] |
ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan.
Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.
|
[8] |
ZAN Ke, CAI Xisheng, WU Yun, WANG Zhao, WANG Dandan, LI Hailiang, JIN Hongyu.
Six Active Ingredients in Medicinal and Non-Medicinal Parts of Farfarae Flos: a Comparative Study
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 67-71.
|
[9] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[10] |
HU Haoran, ZHANG Lei, ZHENG Lei.
Chiral separation and content determination of sotalol hydrochloride by HPLC
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 888-891.
|
[11] |
ZHAO Jun, DONG li, WANG Yang, LIANG Yu, YANG Xue, LI Enze.
Adverse reaction/event reports of esmolol
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 925-930.
|
[12] |
SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang.
Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
|
[13] |
YOU Xiaoyan, ZHENG Yingying, WANG Xianying.
Data-mining and analysis of adverse events signals for infliximab based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 335-340.
|
[14] |
GU Chenchen, ZONG Liuliu, YAO Yamin, SHEN Jie.
Mining of adverse event signals of polatuzumab vedotin based on FAERS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1159-1165.
|
[15] |
ZHAO Wenhua, SHU He, NI Chenming, GUO Jinmin.
Data mining and analysis of adverse drug reaction signals of fampridine sustained-release tablets based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 684-690.
|